Research programme: neuroprotectants - Bionure

Drug Profile

Research programme: neuroprotectants - Bionure

Alternative Names: BN-119; BN-201; G-79

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bionure
  • Class Peptoids; Small molecules
  • Mechanism of Action Protein serine threonine kinase modulators; TrkA receptor agonists; TrkB receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Optic neuritis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neuromyelitis optica
  • No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Glaucoma; Multiple sclerosis; Optic neuritis; Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Glaucoma in Spain (Ophthalmic, Drops)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Spain (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top